Date Title Description PDF
25 Apr 2023 On business and financial situation ROVI commences clinical development of a new three-monthly formulation of Letrozole (Letrozole LEBE) Download
21 Feb 2023 On business and financial situation The Company releases the full year 2022 financial results presentation. Download
21 Feb 2023 On business and financial situation The Company releases the press release related to the full year 2022 financial results. Download
21 Feb 2023 On business and financial situation The company releases the Integrated Report for the year 2022 Download
21 Feb 2023 About Corporate Governance The Company informs about the agreements adopted by the Board of Directors Download

Pages

Date Title Description PDF
01 Oct 2020 Liquidity contracts and specialists Liquidity contract: transactions conducted in the third quarter of 2020 Download
11 Sep 2020 Announcement of general shareholders’ meeting Rovi releases the information related to its 2020 General Shareholders Meeting. Download
27 Jul 2020 On business and financial situation ROVI releases the 2020 First Half Results presentation Download
27 Jul 2020 On business and financial situation The company releases the press release related to the 2020 first half financial results Download
27 Jul 2020 About corporate governance The Company informs about the agreements adopted by the Board of Directors.   Download

Pages

Date Title Description PDF
08 Jan 2018 Contratos de liquidez y contrapartida Liquidity contract: transactions conducted in the fourth quarter of 2017 Download
21 Dec 2017 Préstamos, créditos y avales ROVI and the EIB agree to sign a loan to boost research into drug administration and prolonged-release technologies Download
08 Nov 2017 Información sobre Resultados ROVI releases the press release related to the nine-month period ended 30 September 2017 results Download
08 Nov 2017 Información sobre Resultados ROVI releases the presentation related to the nine-month period ended 30 September 2017 results. Download
24 Oct 2017 Otros sobre negocio y situación financiera The Company releases the presentation related to the update of its Phase III-Prima 3 Risperidone ISM® project. Download

Pages